Investor Presentaiton

38 Strong Balance Sheet to Support Critical Milestones NASDAQ:INO $371.7M Cash and short-term investments As of June 30, 2020 168M Common stock shares outstanding As of August 10, 2020 VGX-3100 ✓ 1Q20: Report interim data from Phase 2 VIN/AIN clinical trials 4Q20: REVEAL 1 Phase 3 top-line efficacy & safety data 2H20: Report full data from Phase 2 VIN/AIN clinical trials MEDI0457 2020: Interim data from AZ on MEDI0457 Phase 2 study in HNSCC INO-3107 1H20: Initiate Phase 1/2 trial of INO-3107 for RRP (HPV6 and 11) ✓ July 2020: Received Orphan Drug Designation from FDA INO-5401 ✓ 2Q20: OS12 data from Phase 1/2 GBM clinical trial (INO-5401 plus LibtayoⓇ) 4Q20: OS18 data from Phase 1/2 GBM clinical trial (INO-5401 plus LibtayoⓇ) INO-4800 ✓ April 2020: Initiate Phase 1 trial of INO-4800 for COVID-19 Sep 2020: Initiate Phase 2/3 trials of INO-4800 for COVID-19 Platform Development 2020: CEPI-funded INO-4700 against MERS into Phase 2 in Middle East & Africa 2020: Interim Phase 1 results from first-in-human trial of dMAb TM plasmid candidate INO-A002 (for preventing or treating Zika virus infection) INOVIO POWERING DNA MEDICINES

View entire presentation